{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:39:32Z","timestamp":1793659172857,"version":"4.5.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["18K08508"],"award-info":[{"award-number":["18K08508"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["19K07475"],"award-info":[{"award-number":["19K07475"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005694","name":"Hori Sciences and Arts Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008644","name":"Japan Diabetes Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008644","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Nonalcoholic steatohepatitis (NASH) is a hepatic phenotype of the metabolic syndrome, and increases the risk of cirrhosis and hepatocellular carcinoma (HCC). Although increasing evidence points to the therapeutic implications of certain types of anti-diabetic agents in NASH, it remains to be elucidated whether their effects on NASH are independent of their effects on diabetes. Genetically obese melanocortin 4 receptor\u2013deficient (MC4R-KO) mice fed Western diet are a murine model that sequentially develops hepatic steatosis, NASH, and HCC in the presence of obesity and insulin resistance. In this study, we investigated the effect of the dipeptidyl peptidase-4 (DPP-4) inhibitor anagliptin on NASH and HCC development in MC4R-KO mice. Anagliptin treatment effectively prevented inflammation, fibrosis, and carcinogenesis in the liver of MC4R-KO mice. Interestingly, anagliptin only marginally affected body weight, systemic glucose and lipid metabolism, and hepatic steatosis. Histological data and gene expression analysis suggest that anagliptin treatment targets macrophage activation in the liver during the progression from simple steatosis to NASH. As a molecular mechanism underlying anagliptin action, we showed that glucagon-like peptide-1 suppressed proinflammatory and profibrotic phenotypes of macrophages\n                    <jats:italic>in vitro<\/jats:italic>\n                    . This study highlights the glucose metabolism\u2013independent effects of anagliptin on NASH and HCC development.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-57935-6","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T06:04:44Z","timestamp":1579673084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis\u2013associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects"],"prefix":"10.1038","volume":"10","author":[{"given":"Mitsuhiro","family":"Kawakubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyako","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozue","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Saka-Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5376-4109","authenticated-orcid":false,"given":"Moritaka","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibuki","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Suganami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"57935_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","volume":"8","author":"T Jojima","year":"2016","unstructured":"Jojima, T. et al. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 8, 45, https:\/\/doi.org\/10.1186\/s13098-016-0169-x (2016).","journal-title":"Diabetol Metab Syndr"},{"key":"57935_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2147\/DMSO.S184767","volume":"11","author":"Y Seko","year":"2018","unstructured":"Seko, Y. et al. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. Diabetes Metab Syndr Obes 11, 835\u2013843, https:\/\/doi.org\/10.2147\/DMSO.S184767 (2018).","journal-title":"Diabetes Metab Syndr Obes"},{"key":"57935_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19658-7","volume":"8","author":"K Shiba","year":"2018","unstructured":"Shiba, K. et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci. Rep. 8, 2362, https:\/\/doi.org\/10.1038\/s41598-018-19658-7 (2018).","journal-title":"Sci. Rep."},{"key":"57935_CR4","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.2741\/2799","volume":"13","author":"CF Deacon","year":"2008","unstructured":"Deacon, C. F., Carr, R. D. & Holst, J. J. DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci. 13, 1780\u20131794 (2008).","journal-title":"Front Biosci."},{"key":"57935_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.numecd.2018.12.009","volume":"29","author":"I Dicembrini","year":"2019","unstructured":"Dicembrini, I., Monami, M. & Mannucci, E. Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge. Nutr Metab Cardiovasc Dis. 29, 215\u2013219, https:\/\/doi.org\/10.1016\/j.numecd.2018.12.009 (2019).","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"57935_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3892\/ijmm.2017.2899","volume":"39","author":"K Nakamura","year":"2017","unstructured":"Nakamura, K. et al. A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob\/ob mice. Int. J. Mol. Med. 39, 969\u2013983, https:\/\/doi.org\/10.3892\/ijmm.2017.2899 (2017).","journal-title":"Int J Mol Med"},{"key":"57935_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3389\/fimmu.2015.00386","volume":"6","author":"D Rohrborn","year":"2015","unstructured":"Rohrborn, D., Wronkowitz, N. & Eckel, J. DPP4 in Diabetes. Front Immunol 6, 386, https:\/\/doi.org\/10.3389\/fimmu.2015.00386 (2015).","journal-title":"Front Immunol"},{"key":"57935_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3892\/mmr.2011.707","volume":"5","author":"M Miyazaki","year":"2012","unstructured":"Miyazaki, M. et al. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol. Med. Rep. 5, 729\u2013733, https:\/\/doi.org\/10.3892\/mmr.2011.707 (2012).","journal-title":"Mol Med Rep"},{"key":"57935_CR9","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1002\/hep.30333","volume":"69","author":"G Farrell","year":"2019","unstructured":"Farrell, G. et al. Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis. Hepatology 69, 2241\u20132257, https:\/\/doi.org\/10.1002\/hep.30333 (2019).","journal-title":"Hepatology"},{"key":"57935_CR10","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.ajpath.2011.07.014","volume":"179","author":"M Itoh","year":"2011","unstructured":"Itoh, M. et al. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am J Pathol 179, 2454\u20132463, https:\/\/doi.org\/10.1016\/j.ajpath.2011.07.014 (2011).","journal-title":"Am J Pathol"},{"key":"57935_CR11","doi-asserted-by":"publisher","unstructured":"Itoh, M. et al. CD11c+ resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis. JCI Insight 2, https:\/\/doi.org\/10.1172\/jci.insight.92902 (2017).","DOI":"10.1172\/jci.insight.92902"},{"key":"57935_CR12","doi-asserted-by":"publisher","first-page":"e82163","DOI":"10.1371\/journal.pone.0082163","volume":"8","author":"M Itoh","year":"2013","unstructured":"Itoh, M. et al. Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLoS One 8, e82163, https:\/\/doi.org\/10.1371\/journal.pone.0082163 (2013).","journal-title":"PLoS One"},{"key":"57935_CR13","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.2337\/db14-0804","volume":"64","author":"AR Aroor","year":"2015","unstructured":"Aroor, A. R. et al. Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function. Diabetes 64, 1988\u20132001, https:\/\/doi.org\/10.2337\/db14-0804 (2015).","journal-title":"Diabetes"},{"key":"57935_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1139\/cjpp-2016-0026","volume":"95","author":"SH Choi","year":"2017","unstructured":"Choi, S. H. et al. Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice. Can J. Physiol. Pharmacol 95, 129\u2013139, https:\/\/doi.org\/10.1139\/cjpp-2016-0026 (2017).","journal-title":"Can J Physiol Pharmacol"},{"key":"57935_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5982","volume":"5","author":"M Tanaka","year":"2014","unstructured":"Tanaka, M. et al. Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis. Nat Commun 5, 4982, https:\/\/doi.org\/10.1038\/ncomms5982 (2014).","journal-title":"Nat Commun"},{"key":"57935_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nature26138","volume":"555","author":"DS Ghorpade","year":"2018","unstructured":"Ghorpade, D. S. et al. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature 555, 673\u2013677, https:\/\/doi.org\/10.1038\/nature26138 (2018).","journal-title":"Nature"},{"key":"57935_CR17","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.2337\/db16-0317","volume":"65","author":"F Zhuge","year":"2016","unstructured":"Zhuge, F. et al. DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1\/M2 Macrophage Polarization. Diabetes 65, 2966\u20132979, https:\/\/doi.org\/10.2337\/db16-0317 (2016).","journal-title":"Diabetes"},{"key":"57935_CR18","doi-asserted-by":"publisher","first-page":"G433","DOI":"10.1152\/ajpgi.00163.2009","volume":"300","author":"T Csak","year":"2011","unstructured":"Csak, T. et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J. Physiol. Gastrointest Liver Physiol 300, G433\u2013441, https:\/\/doi.org\/10.1152\/ajpgi.00163.2009 (2011).","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"57935_CR19","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/gutjnl-2011-300269","volume":"61","author":"D Ye","year":"2012","unstructured":"Ye, D. et al. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 61, 1058\u20131067, https:\/\/doi.org\/10.1136\/gutjnl-2011-300269 (2012).","journal-title":"Gut"},{"key":"57935_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2337\/db13-0757","volume":"63","author":"Y Iwasaki","year":"2014","unstructured":"Iwasaki, Y. et al. Activating transcription factor 4 links metabolic stress to interleukin-6 expression in macrophages. Diabetes 63, 152\u2013161, https:\/\/doi.org\/10.2337\/db13-0757 (2014).","journal-title":"Diabetes"},{"key":"57935_CR21","doi-asserted-by":"publisher","unstructured":"Bannasch, P., Enzmann, H., Klimek, F., Weber, E. & Zerban, H. Significance of sequential cellular changes inside and outside foci of altered hepatocytes during hepatocarcinogenesis. Toxicol Pathol 17, 617\u2013628; discussion 629, https:\/\/doi.org\/10.1177\/0192623389017004107 (1989).","DOI":"10.1177\/0192623389017004107"},{"key":"57935_CR22","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/hep.29677","volume":"67","author":"A Cast","year":"2018","unstructured":"Cast, A. et al. C\/EBP\u03b1-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer. Hepatology 67, 1857\u20131871, https:\/\/doi.org\/10.1002\/hep.29677 (2018).","journal-title":"Hepatology"},{"key":"57935_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.14218\/JCTH.2017.00050","volume":"6","author":"HS Snyder","year":"2018","unstructured":"Snyder, H. S. et al. Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. J. Clin. Transl. Hepatol. 6, 168\u2013174, https:\/\/doi.org\/10.14218\/JCTH.2017.00050 (2018).","journal-title":"J Clin Transl Hepatol"},{"key":"57935_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.trsl.2011.09.005","volume":"159","author":"Y Aso","year":"2012","unstructured":"Aso, Y. et al. Serum level of soluble CD26\/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and\/or sulfonylurea. Transl. Res. 159, 25\u201331, https:\/\/doi.org\/10.1016\/j.trsl.2011.09.005 (2012).","journal-title":"Transl Res"},{"key":"57935_CR25","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti, E., Pinzani, M. & Tsochatzis, E. A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65, 1038\u20131048, https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012 (2016).","journal-title":"Metabolism"},{"key":"57935_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.vph.2017.03.003","volume":"96\u201398","author":"HM Salim","year":"2017","unstructured":"Salim, H. M. et al. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice. Vascul Pharmacol 96\u201398, 19\u201325, https:\/\/doi.org\/10.1016\/j.vph.2017.03.003 (2017).","journal-title":"Vascul Pharmacol"},{"key":"57935_CR27","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1007\/s00125-012-2592-3","volume":"55","author":"YS Lee","year":"2012","unstructured":"Lee, Y. S. et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 55, 2456\u20132468, https:\/\/doi.org\/10.1007\/s00125-012-2592-3 (2012).","journal-title":"Diabetologia"},{"key":"57935_CR28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/jdi.12063","volume":"4","author":"L He","year":"2013","unstructured":"He, L. et al. Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes. J Diabetes Investig 4, 382\u2013392, https:\/\/doi.org\/10.1111\/jdi.12063 (2013).","journal-title":"J Diabetes Investig"},{"key":"57935_CR29","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1194\/jlr.M500294-JLR200","volume":"46","author":"S Cinti","year":"2005","unstructured":"Cinti, S. et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46, 2347\u20132355, https:\/\/doi.org\/10.1194\/jlr.M500294-JLR200 (2005).","journal-title":"J Lipid Res"},{"key":"57935_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cmet.2018.10.001","volume":"29","author":"EM Varin","year":"2019","unstructured":"Varin, E. M. et al. Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition. Cell Metab. 29, 320\u2013334 e325, https:\/\/doi.org\/10.1016\/j.cmet.2018.10.001 (2019).","journal-title":"Cell Metab"},{"key":"57935_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3322\/caac.20078","volume":"60","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci, E. et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 60, 207\u2013221, https:\/\/doi.org\/10.3322\/caac.20078 (2010).","journal-title":"CA Cancer J Clin"},{"key":"57935_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo, P. et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 149, 389\u2013397 e310, https:\/\/doi.org\/10.1053\/j.gastro.2015.04.043 (2015).","journal-title":"Gastroenterology"},{"key":"57935_CR33","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547\u20131554, https:\/\/doi.org\/10.1002\/hep.27368 (2015).","journal-title":"Hepatology"},{"key":"57935_CR34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","volume":"155","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez, E. et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology 155, 443\u2013457 e417, https:\/\/doi.org\/10.1053\/j.gastro.2018.04.034 (2018).","journal-title":"Gastroenterology"},{"key":"57935_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jcmgh.2018.08.008","volume":"7","author":"S Nishina","year":"2019","unstructured":"Nishina, S. et al. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice. Cell Mol Gastroenterol Hepatol 7, 115\u2013134, https:\/\/doi.org\/10.1016\/j.jcmgh.2018.08.008 (2019).","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"57935_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41590-019-0321-5","volume":"20","author":"C Hollande","year":"2019","unstructured":"Hollande, C. et al. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nat. Immunol. 20, 257\u2013264, https:\/\/doi.org\/10.1038\/s41590-019-0321-5 (2019).","journal-title":"Nat Immunol"},{"key":"57935_CR37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cell.2005.08.035","volume":"123","author":"N Balthasar","year":"2005","unstructured":"Balthasar, N. et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123, 493\u2013505, https:\/\/doi.org\/10.1016\/j.cell.2005.08.035 (2005).","journal-title":"Cell"},{"key":"57935_CR38","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.metabol.2013.01.010","volume":"62","author":"K Nakaya","year":"2013","unstructured":"Nakaya, K. et al. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet. Metabolism 62, 939\u2013951, https:\/\/doi.org\/10.1016\/j.metabol.2013.01.010 (2013).","journal-title":"Metabolism"},{"key":"57935_CR39","doi-asserted-by":"publisher","first-page":"172521","DOI":"10.1016\/j.ejphar.2019.172521","volume":"859","author":"S Yamashita","year":"2019","unstructured":"Yamashita, S. et al. Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice. Eur. J. Pharmacol 859, 172521, https:\/\/doi.org\/10.1016\/j.ejphar.2019.172521 (2019).","journal-title":"Eur J Pharmacol"},{"key":"57935_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/MCG.0b013e3181dd1348","volume":"45","author":"R Juluri","year":"2011","unstructured":"Juluri, R. et al. Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J. Clin. Gastroenterol 45, 55\u201358, https:\/\/doi.org\/10.1097\/MCG.0b013e3181dd1348 (2011).","journal-title":"J Clin Gastroenterol"},{"key":"57935_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26383-8","volume":"8","author":"T Goto","year":"2018","unstructured":"Goto, T. et al. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. Sci. Rep. 8, 8157, https:\/\/doi.org\/10.1038\/s41598-018-26383-8 (2018).","journal-title":"Sci Rep"},{"key":"57935_CR42","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1161\/01.ATV.0000183883.72263.13","volume":"25","author":"T Suganami","year":"2005","unstructured":"Suganami, T., Nishida, J. & Ogawa, Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor \u03b1. Arterioscler Thromb Vasc Biol 25, 2062\u20132068 (2005).","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57935-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57935-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57935-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:57:59Z","timestamp":1670288279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57935-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["57935"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-57935-6","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737264420.793571291","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"18 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.T. and M.G. are employees of Sanwa Kagaku Kenkyusho Co., Ltd. The authors declare no further competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"983"}}